부광약품
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
NEWS
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
HOME
CONTACT US
KR
KR
EN
ABOUT BUKWANG
Company Introduction
Vision & Mission
History
Manufacturing Facilities
Subsidiaries & Affiliates
Contact us
R&D
R&D Facilities
Pipeline
Latuda
JM-010
CP-012
Open Innovation
JaguAhr
Protekt
NEWS
News
IR
Financial Information
IR Reports
ANNUAL REPORT
PRODUCTS
Product Search
ETC
OTC
Health Functional Food
Personal Care Products
NEWS
HOME
NEWS
NEWS
NEWS
ALL
Company news
Product news
R&D news
R&D news | Bukwang concluded the 60 patients recruitment for the clinic..
Bukwang Pharmaceutical Co., Ltd. announced that they concluded 60 patients recru..
2021.01.28
R&D news | Bukwang registered composition patent for SOL-804 in Europe
- approved in Europe and Eurasia, Australia, Mexico- Phase 1 study will be condu..
2021.01.14
Company news | Contera Pharma, subsidiary of Bukwang, elected specialists i..
- CEO : Thomas N. Sager , the former development expert of lundbeck- Head of BD ..
2020.12.02
Company news | ImmPACT Bio USA Inc. Raises $18 Million In Series A Financi..
Company is creating innovative cellular therapeutics for solid tumorsCAMARILLO, ..
2020.08.20
R&D news | Bukwang has been granted a patent for its antiviral agent, ..
- Efficacy against SARS-Cov-2- Application under Patent Cooperation Treaty (PCT)..
2020.08.12
Company news | Dyna Therapeutics, subsidiary of Bukwang, registered patent ..
Patent examination ongoing in Korea, USA, Europe, China, India etc.Bukwang Pharm..
2020.07.22
1
2
3
4
5